

EFFECTIVE DATE: 11|03|2015

POLICY LAST UPDATED: 03|16|2022

OVERVIEW

The autonomic nervous system (ANS) controls physiologic processes that are not under conscious control. ANS testing consists of a battery of individual tests intended to evaluate the integrity and function of the ANS. These tests are intended to be adjuncts to the clinical examination in the diagnosis of ANS disorder.

This policy is specific to testing using portable automated devices

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage and Commercial Products

Autonomic nervous system testing using portable automated devices is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products for all indications as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Non-standardized component information of autonomic function testing (AFT) that is determined by a physician to be useful in a patient assessment and clinical decision making given certain patient risks/signs/symptoms, is included in the physician's basic evaluation and management service and is not separately reimbursed service.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet or Subscriber Agreement for limitations of benefits/coverage for services not medically necessary.

BACKGROUND

The autonomic nervous system (ANS) has a primary role in controlling physiologic processes not generally under conscious control. They include heart rate, respirations, gastrointestinal (GI) motility, thermal regulation, bladder control, and sexual function. The ANS is a complex neural regulatory network that consists of 2 complementary systems that work to maintain homeostasis: the sympathetic and the parasympathetic systems. The sympathetic nervous system is responsible for arousal, and sympathetic stimulation leads to increased pulse, increased blood pressure (BP), increased sweating, decreased GI motility, and an increase in other glandular exocrine secretions. This is typically understood as the "fight or flight" response. Activation of the parasympathetic nervous system will mostly have the opposite effects; BP and pulse will decrease, GI motility increases, and there will be a decrease in sweating and other glandular secretions.

Autonomic nervous system (ANS) testing should be performed in a dedicated ANS testing laboratory. Testing in a dedicated laboratory should be performed under closely controlled conditions, and results should be interpreted by an individual with expertise in ANS testing. Testing using automated devices with results interpreted by computer software has not been validated and thus has the potential to lead to erroneous results.

Examples of Automated testing devices are as follows:

ANX 3.0
Sudoscan®
Hrv Acquire
ZYTO Hand Cradle
Bodytronic® 200
Finapres Nova Noninvasive Hemodynamic Monitor

Medicare Advantage Products

The following indications are considered not medically reasonable and necessary and will not be covered:

1. Screening patients without signs or symptoms of autonomic dysfunction, including patients with diabetes, hepatic or renal disease.
2. Testing for the sole purpose of monitoring disease intensity or treatment efficacy in diabetes, hepatic or renal disease.
3. Testing results that are not used in clinical decision-making or patient management.
4. Testing performed by physicians who do not have evidence of training, and expertise to perform and interpret these tests. Physicians must have knowledge, training, and expertise to perform and interpret these tests, and to assess and train personnel working with them. This training and expertise must have been acquired within the framework of an accredited residency and/or fellowship program or must reflect extensive continued medical education activities. If these skills have been acquired by way of continued medical education, the courses must be comprehensive, offered, sponsored or endorsed by an academic [institution] in the United States and/or by the applicable specialty/subspecialty society in the United States, and designated by the American Medical Association (AMA) as category I credit or the American Osteopathic Association (AOA).
5. General professional standards with FDA clearance apply for all equipment used in ANS testing.
6. Testing with ANSAR ANX 3.0 or a similar machine is considered investigational for screening and will not be covered.

CODING

Medicare Advantage and Commercial Products

There is no specific CPT code for Autonomic nervous system testing using portable automated devices.

Claims should be filed with an unlisted CPT code.

95999 Unlisted neurological or neuromuscular diagnostic procedure

The following code has been deleted as of 12/31/2021 and should only be used for claims with a date of service prior to 1/1/2022

The following CPT code is a covered service, but providers will not be separately reimbursed for this service:

95943 Simultaneous, independent, quantitative measures of both parasympathetic function and sympathetic function, based on time frequency analysis of heart rate variability concurrent with time-frequency analysis of continuous respiratory activity, with mean heart rate and blood pressure measures, during rest, paced (deep) breathing, Valsalva maneuvers, and head-up postural change (Deleted 12/31/2021)

RELATED POLICIES

Medicare Advantage Plan National and Local Coverage Determinations

PUBLISHED

Provider Update, May 2022
Provider Update, August 2021
Provider Update, July 2020
Provider Update, June 2019
Provider Update, April 2018
Provider Update, May 2017

REFERENCES

1. Gibbons CH, Cheshire WP, Fife TD. American Academy of Neurology Model Coverage Policy: Autonomic Nervous System Testing. 2014; https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-policies/14autonomicmodel_tr.pdf Accessed April 13, 2021
2. Centers for Medicare and Medicaid (CMS Local Coverage Determination (LCD) L36236- Autonomic Function Testing.
3. Centers for Medicare and Medicaid (CMS Local Coverage Determination (LCD) Billing and Coding: Autonomic Function Testing Article A57024

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

